Non-invasive molecular testing for skin cancer
This article was originally published in Start Up
MiNDERA Corp. is developing an alternative to punch biopsies for diagnosing skin cancer: its microneedle device extracts biomarkers from the skin in a procedure that the start-up says is highly accurate and cost-effective for office-based diagnostic applications in dermatology.
You may also be interested in...
Yuhan’s oncology drug lazertinib is set to expand its indications in Korea to the first-line treatment of EGFR mutation-positive advanced NSCLC, based on new top-line Phase III data showing clinical benefits for all patient sub-groups.
Justices cite changing circumstances, constitutional concerns in preventing government from seeking dismissal of a case in which it initially declined to intervene. They also question whether government should intervene before moving to dismiss.
Ulta has increased its fourth quarter and fiscal 2022 full-year outlook on strong third-quarter comparable store sales growth of 14.5%. Mass beauty is outperforming prestige, but CEO David Kimbell said “it’s hard to know for certain if we are starting to see consumers trade down.”